Mayako Michino

List of Publications by Year
in descending order

23 papers	1,326 citations	567281 15 h-index	713466 21 g-index
23 all docs	23 docs citations	23 times ranked	1989 citing authors

#	Article	IF	Citations
1	Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nature Reviews Drug Discovery, 2009, 8, 455-463.	46.4	260
2	Bridging the NFAT and NF-Î¹B Families. Immunity, 2001, 15, 47-58.	14.3	231
3	Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor. Journal of Medicinal Chemistry, 2012, 55, 6689-6699.	6.4	153
4	A new mechanism of allostery in a G proteinâ€“coupled receptor dimer. Nature Chemical Biology, 2014, 10, 745-752.	8.0	108
5	What Can Crystal Structures of Aminergic Receptors Tell Us about Designing Subtype-Selective Ligands?. Pharmacological Reviews, 2015, 67, 198-213.	16.0	99
6	Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6863-E6870.	7.1	71
7	A Single Glycine in Extracellular Loop 1 Is the Critical Determinant for Pharmacological Specificity of Dopamine D2 and D3 Receptors. Molecular Pharmacology, 2013, 84, 854-864.	2.3	58
8	Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D₃ Receptor. Journal of Medicinal Chemistry, 2017, 60, 580-593.	6.4	49
9	Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D₂ Receptor Through Fragmentation of a Bitopic Ligand. Journal of Medicinal Chemistry, 2015, 58, 6819-6843.	6.4	47
10	Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2503-2510.	2.2	37
11	FoldGPCR: Structure prediction protocol for the transmembrane domain of G proteinâ€coupled receptors from class A. Proteins: Structure, Function and Bioinformatics, 2010, 78, 2189-2201.	2.6	33
12	Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D₂/D₃ Receptor Agonist Selectivity. Journal of Medicinal Chemistry, 2016, 59, 2973-2988.	6.4	33
13	Improved model building and assessment of the Calciumâ€sensing receptor transmembrane domain. Proteins: Structure, Function and Bioinformatics, 2008, 71, 215-226.	2.6	28
14	The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D 2 receptor. Biochemical Pharmacology, 2018, 148, 315-328.	4.4	26
15	The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. PLoS Computational Biology, 2018, 14, e1005948.	3.2	19
16	Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.8	16
17	Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome. Journal of Medicinal Chemistry, 2019, 62, 9246-9253.	6.4	14
18	Deglycase-activity oriented screening to identify DJ-1 inhibitors. RSC Medicinal Chemistry, 2021, 12, 1232-1238.	3.9	13

#	Article	IF	Citations
19	Predicting structurally conserved contacts for homologous proteins using sequence conservation filters. Proteins: Structure, Function and Bioinformatics, 2009, 77, 448-453.	2.6	11
20	A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors. ACS Medicinal Chemistry Letters, 2022, 13, 377-387.	2.8	10
21	Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome. Journal of Medicinal Chemistry, 2021, 64, 6262-6272.	6.4	9
22	Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Human Enzyme through Tight Binding Interactions. ACS Infectious Diseases, 2021, 7, 435-444.	3.8	1
23	Structural Basis for the Allosteric Pharmacology of SB269652 in Dopamine D2 Receptor. Biophysical Journal, 2015, 108, 416a.	0.5	0